KIVEXA

This brand name is authorized in Austria, Australia, Canada, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, United Kingdom, South Africa

Active ingredients

The drug KIVEXA contains a combination of these active pharmaceutical ingredients (APIs):

1	Abacavir UNII J220T4J9Q2 - ABACAVIR SULFATE
	Abacavir is a NRTI. It is a potent selective inhibitor of HIV-1 and HIV-2. Abacavir is metabolised intracellularly to the active moiety, carbovir 5'-triphosphate (TP). In vitro studies have demonstrated that its mechanism of action in relation to HIV is inhibition of the HIV reverse transcriptase enzyme, an event which results in chain termination and interruption of the viral replication cycle.
	Read more about Abacavir
2	Lamivudine UNII 2T8Q726O95 - LAMIVUDINE
	Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription.
	Read more about Lamivudine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KIVEXA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AR02	Lamivudine and abacavir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10357D
CA	Health Products and Food Branch	02269341
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00462309, 00605571, 00910535, 01179691, 01718171, 01746345, 01973130, 02163893, 02163901, 04169730, 04911709, 04980030, 05495130, 06063958, 06560616, 06867674, 07745565, 10335428, 10335440, 11662649, 11722794, 12344472, 12575852, 13825400, 14227061, 14227078, 16529642
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	2931-MEE-0717
EE	Ravimiamet	1198515, 1367344
ES	Centro de información online de medicamentos de la AEMPS	04298002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	101961
FR	Base de données publique des médicaments	69855489
GB	Medicines & Healthcare Products Regulatory Agency	368072, 89918
HK	Department of Health Drug Office	53855
LT	Valstybinė vaistų kontrolės tarnyba	1029332, 1056547
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	479M2005
NL	Z-Index G-Standaard, PRK	136050
NZ	Medicines and Medical Devices Safety Authority	11560
PL	Rejestru Produktów Leczniczych	100137983
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65115001, W65115002
SG	Health Sciences Authority	13230P
ZA	Health Products Regulatory Authority	A39/20.2.8/0030